[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-ductal-adenocarcinoma-mpdac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-ductal-adenocarcinoma-mpdac":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,77,101,124,155,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053709","phase-1-hsk41959-with-standard-therapy-in-solid-tumors-with-mtap-deletion-100053709",false,"NCT07699757","HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion","Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HSK41959 Tablets in Combination With Standard Therapy in Patients With MTAP Deletion Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Adult participants aged 18 years or older.\n2. ECOG performance status of 0 to 1.\n3. Life expectancy of at least 3 months.\n4. Histologically or cytologically confirmed advanced malignant tumor with MTAP deficiency identified by a validated assay.\n5. At least one measurable lesion according to RECIST version 1.1.\n6. For NSCLC cohorts: advanced or metastatic NSCLC meeting protocol-specified disease characteristics and prior treatment requirements.\n7. For PDAC cohorts: advanced or metastatic PDAC meeting protocol-specified disease characteristics and prior treatment requirements.\n8. Adequate bone marrow, hepatic, renal, and coagulation function.\n9. Willingness to provide tumor tissue and\u002For undergo protocol-required biomarker testing, if applicable.\n\nExclusion Criteria:\n\n1. Prior exposure to agents targeting the MAT2A or PRMT5 pathway.\n2. Prior antitumor therapy or unresolved toxicities not meeting protocol-defined washout\u002Frecovery requirements.\n3. Known actionable driver alterations or prior therapies excluded by the protocol for specific NSCLC cohorts (for example EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, KRAS G12C, HER2, as applicable).\n4. Significant gastrointestinal disorders that may affect drug absorption.\n5. Clinically significant cardiovascular disease, including clinically relevant QTc prolongation, reduced left ventricular ejection fraction, or severe heart failure.\n6. Uncontrolled metabolic disease, uncontrolled hypertension, or active infection.\n7. Known HIV infection, active hepatitis B with significant viral replication, or active hepatitis C infection.\n8. Use of prohibited concomitant medications, including strong inhibitors or inducers of CYP3A4, P-gp, BCRP, or other protocol-specified transporters\u002Fenzymes within the required washout period.\n9. Other serious medical or psychiatric conditions that, in the investigator's judgment, would make study participation inappropriate.","ALL","18 Years",{"count":19,"type":20},258,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors. The study consists of dose-escalation and dose-expansion parts and is intended to evaluate the safety, tolerability, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HSK41959 tablets when used together with standard therapy.",[26,27,28],"Non-Small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma (mPDAC)","Advanced Solid Tumors","NOT_YET_RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-07",{"date":37,"type":20},"2029-11",{"name":39,"class":40},"Haisco Pharmaceutical Group Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":41},"100576846","phase-2-cemiplimab-plus-gemcitabine-in-patients-with-metastatic-pancreatic-adenocarcinoma-100576846","NCT06790602","Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch\u002FSucrose Non-Fermentable (SWI\u002FSNF) Alterations.","SWITCH","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Ability to understand the nature of this study, comply with study and follow-up procedures, and give written informed consent.\n3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. Primary tumor can be intact or post-resection with newly developed metastatic disease.\n4. Stage IV disease (measurable disease by Immunotherapeutics Response Evaluation Criteria in Solid Tumors is required).\n5. Alterations in SWI\u002FSNF complex chromatin remodeling genes (ARID1A, ARID1B, PBRM1, SMARCA4 and SMARCB1, etc.) detected by next generation sequencing performed prior to enrollment on an ultrasound-guided core biopsy of the primary tumor.\n6. One previous line of therapy for pancreatic ductal adenocarcinoma (NOT immunotherapy or cellular therapy).\n7. Last dose of chemotherapy administered \\> 14 days prior to the initiation of study therapy.\n8. Last dose of radiation therapy or administered \\> 28 days prior to the initiation of study therapy.\n9. Eastern Cooperative Oncology Group performance score of 0-1.\n10. Adequate bone marrow function: Absolute neutrophil count ≥ 1,500 cells per microliter; Platelet count ≥ 100,000 cells per microliter; Hemoglobin ≥ 9.0 grams per deciliter.\n11. Adequate hepatic function: Total bilirubin ≤ 1.5 times upper limit of normal (NOTE high bilirubin levels due to Gilbert's syndrome are allowed); Aspartate transaminase ≤ 3.0 times upper limit of normal (≤5.0 times upper limit of normal if liver metastases are present); Alanine transaminase ≤ 3.0 times upper limit of normal (≤5.0 times upper limit of normal if liver metastases are present).\n12. Adequate renal function: Serum creatinine ≤ 1.5 times upper limit of normal.\n13. Calculated corrected QT Interval (QTcF) average of the triplicate electrocardiograms \\\u003C470 milliseconds.\n14. Participants not of child-bearing potential, or participants of child-bearing potential who agree to use adequate contraceptive measures during the study and for at least 6 months after the last cemiplimab dose; who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to initiation of study therapy.\n15. For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner during study participation and for at least 6 months after the last cemiplimab dose.\n\nExclusion Criteria:\n\n1. Two or more lines of systemic or previous investigational therapy for metastatic pancreatic ductal adenocarcinoma.\n2. History of any autoimmune disease requiring treatment within the past 12 months prior to enrollment.\n3. History of transplanted organ\u002Fbone marrow.\n4. History of interstitial lung disease.\n5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.\n6. History of previous malignancy (except in-situ cancer or basal or squamous cell skin cancer) within past 3 years prior to enrollment.\n7. History of immune checkpoint inhibitor therapy, ever.\n8. Known bleeding disorders (e.g., van Willebrand's disease or hemophilia).\n9. Current use of warfarin or other vitamin K antagonists. NOTE: if therapeutic anticoagulation is necessary, low molecular weight heparin or oral factor Xa inhibitors are the anticoagulants of choice.\n10. Current use of a strong cytochrome P450 3A inhibitor (for example, antifungal medications, grapefruit juice, amiodarone, etc.).\n11. Presence of known central nervous system or brain metastases.\n12. History of other diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.\n13. Life expectancy of \\\u003C3 months.\n14. Known active, not-controlled human immunodeficiency virus, hepatitis B or hepatitis C infection or diagnosis of immunodeficiency.\n15. Receipt of a live vaccine within 4 weeks of start of study medication.\n16. Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment.\n17. Major surgery within 4 weeks of the start of study treatment. Major surgeries are defined as those surgeries that require general anesthesia. Insertion of a vascular access device, biliary drainage tube, gastrointestinal stent are NOT considered major surgery.\n18. Pregnancy or lactation.\n19. Known allergic reactions to components of the study intervention, cemiplimab and\u002For gemcitabine.",{"count":51,"type":20},43,[53],"PHASE2","This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch\u002FSucrose Non-Fermentable (SWI\u002FSNF) alterations who have already been treated with FOLFIRINOX (5-fluoruracil, leucovorin, irinotecan, oxaliplatin) or gemcitabine\u002Fnab-paclitaxel chemotherapy.",[27],[57,58,59,60,61,62,63,64,65],"cemiplimab","gemcitabine","immune checkpoint inhibitors","pancreatic ductal adenocarcinoma","SWI\u002FSNF","combination therapy","PDAC","Phase 2","metastatic","RECRUITING","2026-06-04",{"date":69,"type":33},"2026-06-08",{"date":71,"type":33},"2026-05-06",{"date":73,"type":20},"2029-12",{"name":75,"class":76},"University of California, San Diego","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100629952","phase-1-a-first-in-human-phase-iiia-study-to-evaluate-da-3501-in-patients-with-advanced-gastric-or-gastro-esophageal-junction-adenocarcinoma-and-pancreatic-ductal-adenocarcinoma-100629952","NCT07481357","A First-In-Human Phase I\u002FIIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","A First-In-Human Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n1. Patients aged ≥ 19 years\n2. Histologically or cytologically documented advanced CLDN18.2+ GC\u002FGEJ adenocarcinoma or advanced CLDN18.2+ PDAC\n3. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\n4. Life expectancy ≥12 weeks as judged by the Investigator\n\nExclusion Criteria:\n\n1. Cardiac abnormalities\n2. Gastrointestinal abnormalities\n3. Active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), known hepatitis C virus (HCV), known human immunodeficiency virus (HIV).\n4. Active systemic infection requiring IV antibiotics therapy.","19 Years",{"count":86,"type":20},51,[23],"The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC\u002FGEJ and advanced CLDN18.2+ PDAC.\n\nParticipants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.",[90,91,27],"Gastric (Stomach) Cancer","GastroEsophageal Cancer","2026-05-18",{"date":94,"type":33},"2026-05-20",{"date":92,"type":33},{"date":97,"type":20},"2029-02",{"name":99,"class":40},"Dong-A ST Co., Ltd.",3,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100566435","oscar-ii-study---the-oncobind-ctc-removal-study-100566435","NCT06655142","OSCAR II STUDY - The ONCObind CTC Removal Study","Prospective Matched Control Feasibility Study to Determine the Capacity of the Onco-Seraph 100 Microbind® Affinity Blood Filter ( ONCObind Procedure) to Remove Circulating Tumor Cells From the Blood in Patients With Either Metastatic Pancreatic Adenocarcinoma or Metastatic Colorectal Carcinoma","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a patient must meet all of the following criteria:\n\n1. Patients ≥ 18 years of age with\n\n   1. mPDAC cohort: Metastatic pancreatic ductal cancer who experienced disease progression or not tolerating fluoropyrimidine-, oxaliplatin- and irinotecan- based regimens or prior treatment with gemcitabine and nab-paclitaxel or are not a candidate for chemotherapy\n   2. mCRC Cohort : Metastatic CRC who experienced disease progression on 5-fluorouracil (5-FU), capecitabine, oxaliplatin and irinotecan as FOLFIRI and\u002For FOLFOX and\u002For XELOX and\u002For XELIRI and\u002For FOLFOXIRI\u002FFOLFIRINOX or who are not candidates for chemotherapy.\n2. Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 2 or less.\n3. Patient or legally authorized representative is willing and able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.\n4. Patients with a CTC concentration of at least 5 cells\u002FmL\n5. Must be willing to provide blood samples for prospective tumor molecular profiling and exploratory analyses.\n6. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.\n7. Patients must be of non-childbearing potential or using a medically acceptable contraceptive regimen. Effective contraception includes surgical sterilization (e.g., vasectomy, tubal ligation), two forms of barrier methods (e.g., condom, diaphragm) used with spermicide, IUDs.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnant or breast feeding\n2. Patients who cannot tolerate the placement of a tunneled catheter for vascular access to enable extracorporeal treatment.\n3. Patients with a history of heparin induced thrombocytopenia (HIT).\n4. Patients with known allergy to heparin sodium.\n5. High risk of bleeding (platelet count \\\u003C50mm3 or International Normalized Ratio (INR) \\>1.5)\n6. Hemodynamic instability and inability to tolerate extracorporeal therapy (defined as MAP\\\u003C65 despite fluids and vasopressors and or sustained hypotension at enrollment as defined by two readings with systolic blood pressure (SBP) measurements below 100 mmHg or diastolic blood pressure (DBP) measurements below 50 mmHg. The measurements must be performed thirty minutes from one another, and the Subject must be resting for at least 5 minutes prior to obtaining each measurement. (If the first reading includes a SBP greater than 100 mmHg and a DBP greater than 50 mmHg, the second reading does not need to be taken).\n7. Uncontrolled hypertension despite optimal management (systolic blood pressure \\>180mmHg\n8. Ongoing uncontrolled, serious infection.\n9. Renal failure requiring dialysis.\n10. Patients with a life expectancy of less than 30 days.\n11. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to initiation of treatment on this study.\n12. Concurrent participation in any interventional clinical trial or has been previously entered in this trial.\n13. The Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator.\n14. Unable to obtain informed consent from either patient or legally authorized representative (LAR)\n15. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.",{"count":109,"type":20},120,[111],"NA","This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC refractory to systemic therapy. Site selection will be dependent upon the site's familiarity with extracorporeal blood purification platforms as well as the diagnosis and management of mPDAC and mCRC. Adults (18 years old and older, ECOG PS of equal or less than 2) with a diagnosis of either mPDAC as defined histologically (microscopically) as a \"pancreatobiliary type\" adenocarcinoma who experienced disease progression or not tolerating fluoropyrimidine-, oxaliplatin- and irinotecan- based regimens or prior treatment with gemcitabine and nab-paclitaxel or are not candidates for chemotherapy or mCRC patients who experienced disease progression on 5-fluorouracil (5-FU), capecitabine, oxaliplatin and irinotecan as FOLFIRI and\u002For FOLFOX and\u002For XELOX and\u002For XELIR and\u002For FOLFOXIRI\u002FFOLFIRINOX or who are not candidates for chemotherapy with at least 5 cells\u002FmL CTCs in peripheral blood and\u002For portal vein.",[27,114],"Metastatic Colorectal Carcinoma (mCRC)","2026-04-15",{"date":117,"type":33},"2026-04-17",{"date":119,"type":20},"2027-01-15",{"date":121,"type":20},"2028-07",{"name":123,"class":40},"ExThera Medical Corporation",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100632646","study-of-a-polygenic-risk-score-to-predict-the-risk-of-pancreatic-ductal-adenocarcinoma-100632646","NCT07516392","Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma","PRE-PDAC: Evaluation of Polygenic Risk scorE for Pancreatic Ductal AdenoCarcinoma Risk Prediction: a Case-control Study","PRE-PDAC","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Able and willing to provide informed consent.\n* For cases: participants with pancreatic ductal adenocarcinoma.\n* For controls: participants without pancreatic ductal adenocarcinoma.\n* Availability of the clinical and\u002For biological data required for the study, including data necessary for polygenic risk score evaluation.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Inability to provide informed consent.\n* Incomplete or unavailable clinical and\u002For biological data required for the study.\n* Any condition that, in the judgment of the investigators, makes the participant unsuitable for inclusion",true,{"count":134,"type":20},1140,[111],"This case-control study aims to evaluate the role of a polygenic risk score in predicting the risk of pancreatic ductal adenocarcinoma (PDAC). The study will compare genetic risk profiles between individuals with PDAC and controls without the disease in order to assess whether a polygenic risk score may help identify individuals at higher risk. The findings may contribute to improving risk stratification and supporting future strategies for early identification and prevention of pancreatic cancer.",[27],[139,140,141,60,142,143,144,145],"Pancreatic Cancer","polygenic risk score","PRS","case-control study","risk prediction","genetic susceptibility","pancreatic neoplasms","2026-03-30",{"date":148,"type":33},"2026-04-08",{"date":150,"type":20},"2026-04-01",{"date":152,"type":20},"2026-09-30",{"name":154,"class":76},"Catholic University of the Sacred Heart",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100604084","immunoparalysis-after-pancreaticoduodenectomy-100604084","NCT07144917","Immunoparalysis After Pancreaticoduodenectomy","Immunoparalysis After Pancreaticoduodenectomy : a Pilot Multicentric Prospective Study Based on mHLA-DR Expression","ImPaHLA","Inclusion Criteria:\n\n* Any patient undergoing a Pancreaticoduodenectomy in one of the four participating centers for a benign or malignant tumor of the pancreatic head\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant, postpartum, or breastfeeding women\n* Indication other than tumor-related (e.g., chronic pancreatitis)\n* Patient with an infectious syndrome at the time of inclusion\n* Preoperative immunosuppression\n* Immunosuppressive disease other than cancer:\n\n  * Congenital or acquired immune deficiency\n  * Functional hyposplenism or asplenia, patient under long-term antibiotic prophylaxis for this reason\n  * Patient with HIV (and CD4 \\\u003C cells\u002Fmm³)\n  * Aplasia defined by circulating neutrophil count \\\u003C 500 cells\u002Fmm³\n  * Immunosuppressive treatment other than chemotherapy : Biotherapy, Corticosteroid therapy \\>10 mg\u002Fday or cumulative dose \\>700 mg prednisolone equivalent : Patient expected to receive immunosuppressive treatment within the first 7 postoperative days\n* Individuals deprived of liberty by judicial or administrative decisio\n* Adults under legal protection (guardianship or curatorship)\n* Individuals not affiliated with a social security scheme or an equivalent coverage\n* Refusal to participate in the study",{"count":164,"type":20},100,"OBSERVATIONAL","By 2030, pancreatic adenocarcinoma could become the second leading cause of cancer-related death in France. To date, Pancreaticoduodenectomy (PD) is the standard treatment for resectable adenocarcinoma of the pancreatic head. Despite advances in perioperative care, morbidity remains high, and the occurrence of postoperative complications can negatively impact patient's oncologic prognosis.\n\nSepsis is the leading cause of postoperative death following PD and it remains mainly associated with the development of a clinically-relevant postoperative pancreatic fistula (CR-POPF). More recently, post-pancreatectomy acute pancreatitis (PPAP) has been defined as a very early complication after pancreatic resection. PPAP is an ischemic and inflammatory condition of the pancreatic remnant that may be responsible for nearly half of CR-POPFs. CR-PPAP can lead to sepsis with multiorgan failure and necrotizing pancreatitis, which are with CR-POPF the two main indications for reoperation and completion pancreatectomy.\n\nDespite the major impact of severe pancreatic complications on mortality after PD, no reliable early biomarker currently exists to predict their occurence.\n\nImmunoparalysis refers to the functional impairment of immune cells with monocytes showing altered capacity of cell presentation. In classical models of inflammation such as acute pancreatitis, sepsis and surgery, the initial systemic inflammatory response syndrome is simultaneously accompanied by a compensatory anti-inflammatory reaction, which may lead to immunoparalysis. mHLA-DR (Human Leukocyte Antigen-DR on Monocytes) is considered as the most appropriate biomarker to assess this immune dysfonction. Various studies emphasize the predictive value of mHLA-DR for early detection of adverse outcomes : in acute pancreatitis, mHLA-DR predicts the onset of severe forms as early as admission and after colorectal surgery, mHLA-DR enables earlier detection of anastomotic leakage compared to conventional biomarkers.\n\nThe main hypothesis is that the severity of postoperative complications is driven by immunological factors. On one hand, this study seeks to improve the understanding of the relationship between the immune response after PD and the occurrence of pancreatic complications. On the other hand, it aims to assess if mHLA-DR could represent an early biomarker for detecting severe pancreatic complications.\n\nTherefore, the main objective of this study is to evaluate the association of mHLA-DR expression in the early postoperative period following PD and the occurrence of severe pancreatic complications",[27,168,169],"Pancreatic Head Tumour","Pancreatic Fistula",[171,172,173,174,175,176,177,178,179],"Pancreaticoduocenectomy","Pancreatic fistula","Post-Operative Pancreatic Fistula","Post-Pancreatectomy Acute Pancreatitis","Pancreatic complications","Sepsis","mHLA-DR","Immunparalysis","Immunosuppression","2026-03-25",{"date":146,"type":33},{"date":183,"type":33},"2026-03-18",{"date":185,"type":20},"2027-06-18",{"name":187,"class":76},"Hospices Civils de Lyon",4,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100627146","how-does-pre-operative-biliary-drainage-in-pancreatic-adenocarcinoma-affect-surgical-outcomes-in-pancreatic-cancer-surgery-100627146","NCT07444840","How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery","Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma and Its Effect on Surgical Oncological Outcomes","PBDSOO","Inclusion Criteria:\n\n* Procedure - Pancreaticoduodenectomy\n* Histology - Pancreatic ductal adenocarcinoma at East Lancashire Hospitals NHS Trust\n* Age \\> 18 years\n\nExclusion Criteria:\n\nPatients \\\u003C 18 years of age Patients who had pancreaticoduodenectomy for benign disease Patients who had pancreaticoduodenectomy with any histology other than pancreatic ductal adenocarcinoma Patients who underwent any other procedure for head of pancreas pancreatic ductal adenocarcinoma Patients who have opted out from being part of research as per the MESH database",{"count":198,"type":20},90,"Pre-operative biliary drainage (PBD) is a procedure used to relieve bile duct obstruction, a common issue in patients with pancreatic cancer. The obstruction occurs when a tumor blocks the bile duct, leading to jaundice and other complications. While PBD can help resolve jaundice and improve liver function, its impact on the overall outcomes of pancreatic cancer surgery is still debated.\n\nRecent research has focused on whether PBD before surgery improves patient outcomes, such as surgical success, recovery time, and long-term survival. Some studies suggest that draining the bile before surgery might reduce complications like infections, liver dysfunction, and jaundice-related risks. On the other hand, other research indicates that PBD could increase the chances of infection, delays in surgery, or complications from the procedure itself, such as bile leakage or inflammation.\n\nThis study will look at patients undergoing pancreaticoduodenectomy to remove their head of pancreas pancreatic ductal adenocarcinoma over 8 years, and will compare the tumour characteristics of patients who have had PBD vs those who have not. Data will be gathered from the already available histological characteristics. No treatment would be affected and no tissue would be affected.\n\nThis research study will focus on oncological characteristics such as tumour progression and lymphatic spread, with overall patient survival as secondary outcome measures.",[27,201],"Pancreatic Ductal Adenocarcinoma (PDAC)",[60,203,204,205,206,207],"biliary drainage","oncology","T stage","perineural invasion","lymphovascular invasion","2026-02-25",{"date":210,"type":33},"2026-03-03",{"date":212,"type":20},"2026-03-01",{"date":214,"type":20},"2026-05-01",{"name":216,"class":76},"East Lancashire Hospitals NHS Trust"]